Sökning: onr:"swepub:oai:gup.ub.gu.se/163572" > Lapatinib with tras...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 04261naa a2201177 4500 | |
001 | oai:gup.ub.gu.se/163572 | |
003 | SwePub | |
008 | 240528s2012 | |||||||||||000 ||eng| | |
024 | 7 | a https://gup.ub.gu.se/publication/1635722 URI |
024 | 7 | a https://doi.org/10.1016/S0140-6736(11)61847-32 DOI |
040 | a (SwePub)gu | |
041 | a eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Baselga, José4 aut |
245 | 1 0 | a Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. |
264 | 1 | c 2012 |
520 | a The anti-HER2 monoclonal antibody trastuzumab and the tyrosine kinase inhibitor lapatinib have complementary mechanisms of action and synergistic antitumour activity in models of HER2-overexpressing breast cancer. We argue that the two anti-HER2 agents given together would be better than single-agent therapy. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Kirurgi0 (SwePub)302122 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Surgery0 (SwePub)302122 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
653 | a Administration | |
653 | a Oral | |
653 | a Adult | |
653 | a Aged | |
653 | a Antibodies | |
653 | a Monoclonal | |
653 | a Humanized | |
653 | a administration & dosage | |
653 | a adverse effects | |
653 | a Antineoplastic Combined Chemotherapy Protocols | |
653 | a adverse effects | |
653 | a therapeutic use | |
653 | a Breast Neoplasms | |
653 | a chemistry | |
653 | a drug therapy | |
653 | a pathology | |
653 | a surgery | |
653 | a Chemotherapy | |
653 | a Adjuvant | |
653 | a Diarrhea | |
653 | a chemically induced | |
653 | a Drug Administration Schedule | |
653 | a Female | |
653 | a Humans | |
653 | a Infusions | |
653 | a Intravenous | |
653 | a Liver | |
653 | a drug effects | |
653 | a metabolism | |
653 | a Middle Aged | |
653 | a Neoadjuvant Therapy | |
653 | a methods | |
653 | a Paclitaxel | |
653 | a administration & dosage | |
653 | a adverse effects | |
653 | a Quinazolines | |
653 | a administration & dosage | |
653 | a adverse effects | |
653 | a Receptor | |
653 | a erbB-2 | |
653 | a analysis | |
653 | a antagonists & inhibitors | |
653 | a Treatment Outcome | |
653 | a Tumor Markers | |
653 | a Biological | |
653 | a analysis | |
653 | a antagonists & inhibitors | |
700 | 1 | a Bradbury, Ian4 aut |
700 | 1 | a Eidtmann, Holger4 aut |
700 | 1 | a Di Cosimo, Serena4 aut |
700 | 1 | a de Azambuja, Evandro4 aut |
700 | 1 | a Aura, Claudia4 aut |
700 | 1 | a Gómez, Henry4 aut |
700 | 1 | a Dinh, Phuong4 aut |
700 | 1 | a Fauria, Karine4 aut |
700 | 1 | a Van Dooren, Veerle4 aut |
700 | 1 | a Aktan, Gursel4 aut |
700 | 1 | a Goldhirsch, Aron4 aut |
700 | 1 | a Chang, Tsai-Wang4 aut |
700 | 1 | a Horváth, Zsolt4 aut |
700 | 1 | a Coccia-Portugal, Maria4 aut |
700 | 1 | a Domont, Julien4 aut |
700 | 1 | a Tseng, Ling-Min4 aut |
700 | 1 | a Kunz, Georg4 aut |
700 | 1 | a Sohn, Joo Hyuk4 aut |
700 | 1 | a Semiglazov, Vladimir4 aut |
700 | 1 | a Lerzo, Guillermo4 aut |
700 | 1 | a Palacova, Marketa4 aut |
700 | 1 | a Probachai, Volodymyr4 aut |
700 | 1 | a Pusztai, Lajos4 aut |
700 | 1 | a Untch, Michael4 aut |
700 | 1 | a Gelber, Richard D4 aut |
700 | 1 | a Piccart-Gebhart, Martine4 aut |
700 | 1 | a Holmberg, Stig B,d 1946u Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för kirurgi,Institute of Clinical Sciences, Department of Surgery4 aut |
710 | 2 | a Göteborgs universitetb Institutionen för kliniska vetenskaper, Avdelningen för kirurgi4 org |
773 | 0 | t Lancetg 379:9816, s. 633-40q 379:9816<633-40x 1474-547X |
856 | 4 8 | u https://gup.ub.gu.se/publication/163572 |
856 | 4 8 | u https://doi.org/10.1016/S0140-6736(11)61847-3 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy